{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:35:52Z","timestamp":1793795752139,"version":"4.6.1"},"reference-count":173,"publisher":"Centers for Disease Control MMWR Office","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr7206a1","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:49:54Z","timestamp":1699969794000},"page":"1-47","source":"Crossref","is-referenced-by-count":51,"title":["CDC Guidelines for the Prevention and Treatment of Anthrax, 2023"],"prefix":"10.15585","volume":"72","author":[{"given":"William A.","family":"Bower","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa K.","family":"Person","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan L.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M.","family":"Hesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen B.","family":"Bulitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolf W.","family":"Karchmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana Godfred","family":"Cato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Chatham","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2460\/javma.233.1.63","article-title":"Zoonosis update. Anthrax.","volume":"233","author":"Shadomy","year":"2008","journal-title":"J Am Vet Med Assoc"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(10)60573-9","article-title":"Anthrax infection in drug users.","volume":"375","author":"Booth","year":"2010","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/pathogens11060690","article-title":"What is anthrax?","volume":"11","author":"Bower","year":"2022","journal-title":"Pathogens"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.4269\/ajtmh.2007.77.1103","article-title":"Modeling the geographic distribution of Bacillus anthracis, the causative agent of anthrax disease, for the contiguous United States using predictive ecological [corrected] niche modeling.","volume":"77","author":"Blackburn","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4269\/ajtmh.19-0191","article-title":"Predicting the geographic distribution of the Bacillus anthracis A1.a\/Western North American sub-lineage for the continental United States: new outbreaks, new genotypes, and new climate data.","volume":"102","author":"Yang","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R6","first-page":"280","article-title":"Inhalation anthrax associated with dried animal hides\u2014Pennsylvania and New York City, 2006.","volume":"55","author":"CDC","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3201\/eid2002.130021","article-title":"Investigation of inhalation anthrax case, United States.","volume":"20","author":"Griffith","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R8","first-page":"872","article-title":"Gastrointestinal anthrax after an animal-hide drumming event\u2014New Hampshire and Massachusetts, 2009.","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R9","first-page":"628","article-title":"Cutaneous anthrax associated with drum making using goat hides from West Africa\u2014Connecticut, 2007.","volume":"57","author":"DC","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R10","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.3201\/eid2612.200470","article-title":"Control and prevention of anthrax, Texas, USA, 2019.","volume":"26","author":"Sidwa","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3390\/pathogens11040402","article-title":"Welder\u2019s anthrax: a review of an occupational disease.","volume":"11","author":"de Perio","year":"2022","journal-title":"Pathogens"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R12","unstructured":"CDC; US Department of Agriculture. Federal select agent program: select agent and toxins FAQS. Washington, DC: US Department of Agriculture; 2021. https:\/\/www.selectagents.gov\/faq-general.html"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3201\/eid0810.020399","article-title":"Bioterrorism-related anthrax surveillance, Connecticut, September\u2013December, 2001.","volume":"8","author":"Williams","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R15","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1126\/science.7973702","article-title":"The Sverdlovsk anthrax outbreak of 1979.","volume":"266","author":"Meselson","year":"1994","journal-title":"Science"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R16","unstructured":"World Health Organization. Health aspects of chemical and biological weapons: report of a WHO group of consultants. Geneva, Switzerland: World Health Organization; 1970."},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6404a1","article-title":"Clinical framework and medical countermeasure use during an anthrax mass-casualty incident.","volume":"64","author":"Bower","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1128\/iai.49.2.291-297.1985","article-title":"Demonstration of a capsule plasmid in Bacillus anthracis.","volume":"49","author":"Green","year":"1985","journal-title":"Infect Immun"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R19","first-page":"446","article-title":"The chemical basis of the virulence of Bacillus anthracis. IX. Its aggressins and their mode of action.","volume":"44","author":"Keppie","year":"1963","journal-title":"Br J Exp Pathol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R20","first-page":"557","article-title":"Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 MDa and 60 MDa plasmids.","volume":"132","author":"Uchida","year":"1986","journal-title":"J Gen Microbiol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.tim.2014.02.012","article-title":"Anthrax lethal and edema toxins in anthrax pathogenesis.","volume":"22","author":"Liu","year":"2014","journal-title":"Trends Microbiol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-micro-091014-104523","article-title":"Anthrax pathogenesis.","volume":"69","author":"Moayeri","year":"2015","journal-title":"Annu Rev Microbiol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R23","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.3390\/toxins7083167","article-title":"Anthrax toxins in context of Bacillus anthracis spores and spore germination.","volume":"7","author":"Cote","year":"2015","journal-title":"Toxins (Basel)"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R24","doi-asserted-by":"publisher","first-page":"7123","DOI":"10.1016\/S0021-9258(17)38364-3","article-title":"Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.","volume":"261","author":"Friedlander","year":"1986","journal-title":"J Biol Chem"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mib.2003.12.001","article-title":"The roles of anthrax toxin in pathogenesis.","volume":"7","author":"Moayeri","year":"2004","journal-title":"Curr Opin Microbiol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1128\/IAI.72.1.430-439.2004","article-title":"Anthrax lethal toxin induces human endothelial cell apoptosis.","volume":"72","author":"Kirby","year":"2004","journal-title":"Infect Immun"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R27","doi-asserted-by":"publisher","first-page":"e130687","DOI":"10.3201\/eid2002.130687","article-title":"Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults.","volume":"20","author":"Hendricks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","article-title":"Systematic review: a century of inhalational anthrax cases from 1900 to 2005.","volume":"144","author":"Holty","year":"2006","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1212\/WNL.59.3.327","article-title":"Anthrax meningoencephalitis.","volume":"59","author":"Lanska","year":"2002","journal-title":"Neurology"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R30","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/cid\/ciw184","article-title":"Identifying meningitis during an anthrax mass casualty incident: systematic review of systemic anthrax since 1880.","volume":"62","author":"Katharios-Lanwermeyer","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/AOG.0b013e3182a5fdfd","article-title":"Prophylaxis and treatment of anthrax in pregnant women.","volume":"122","author":"Meaney-Delman","year":"2013","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R32","doi-asserted-by":"publisher","first-page":"e1411","DOI":"10.1542\/peds.2014-0563","article-title":"Pediatric anthrax clinical management.","volume":"133","author":"Bradley","year":"2014","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6804a1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019.","volume":"68","author":"Bower","year":"2019","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R34","doi-asserted-by":"publisher","first-page":"S373","DOI":"10.1093\/cid\/ciac520","article-title":"Systematic review of in vitro antimicrobial susceptibility testing for Bacillus anthracis, 1947\u20132019.","volume":"75","author":"Maxson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R35","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.1093\/cid\/ciac591","article-title":"Postexposure prophylaxis and treatment of Bacillus anthracis infections: a systematic review and meta-analyses of animal models, 1947\u20132019.","volume":"75","author":"Kennedy","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/hs.2015.0032","article-title":"Antitoxin treatment of inhalation anthrax: a systematic review.","volume":"13","author":"Huang","year":"2015","journal-title":"Health Secur"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R37","doi-asserted-by":"publisher","first-page":"S432","DOI":"10.1093\/cid\/ciac532","article-title":"Antitoxin use in the prevention and treatment of anthrax disease: a systematic review.","volume":"75","author":"Hesse","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R38","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1093\/cid\/ciac534","article-title":"Clinical features of patients hospitalized for all routes of anthrax, 1880\u20132018: a systematic review.","volume":"75","author":"Hendricks","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R39","doi-asserted-by":"publisher","first-page":"S392","DOI":"10.1093\/cid\/ciac536","article-title":"Systematic review of hospital treatment outcomes for naturally acquired and bioterrorism-related anthrax, 1880\u20132018.","volume":"75","author":"Person","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R40","doi-asserted-by":"publisher","first-page":"S459","DOI":"10.1093\/cid\/ciac533","article-title":"Risk factors for death or meningitis in adults hospitalized for cutaneous anthrax, 1950\u20132018: a systematic review.","volume":"75","author":"Thompson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R41","doi-asserted-by":"publisher","first-page":"S468","DOI":"10.1093\/cid\/ciac546","article-title":"Algorithms for the identification of anthrax meningitis during a mass casualty event based on a systematic review of systemic anthrax from 1880 through 2018.","volume":"75","author":"Binney","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R42","doi-asserted-by":"publisher","first-page":"S417","DOI":"10.1093\/cid\/ciac592","article-title":"Safety of antimicrobials for postexposure prophylaxis and treatment of anthrax: a review.","volume":"75","author":"Parker","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R43","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/01.inf.0000094940.81959.14","article-title":"Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation.","volume":"22","author":"Bradley","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R44","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.2174\/138920111798808428","article-title":"Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.","volume":"12","author":"Bulitta","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R45","unstructured":"Standards of Ethical Conduct for Employees of the Executive Branch. 5 CFR \u00a7 2635 (2020)."},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R46","doi-asserted-by":"publisher","first-page":"S402","DOI":"10.1093\/cid\/ciac572","article-title":"Evaluation of amoxicillin and amoxicillin-clavulanate (Augmentin) for antimicrobial postexposure prophylaxis following Bacillus anthracis inhalational exposure in cynomolgus macaques.","volume":"75","author":"Slay","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R47","doi-asserted-by":"publisher","first-page":"S411","DOI":"10.1093\/cid\/ciac569","article-title":"Determination of the postexposure prophylactic benefit of oral azithromycin and clarithromycin against inhalation anthrax in cynomolgus macaques.","volume":"75","author":"Slay","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R48","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.1093\/cid\/ciac535","article-title":"Welder\u2019s anthrax: a tale of 2 cases.","volume":"75","author":"Hendricks","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R49","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.1093\/cid\/ciac531","article-title":"Survival of patient with hemorrhagic meningitis associated with inhalation anthrax.","volume":"75","author":"Lombarte Espinosa","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R50","doi-asserted-by":"publisher","first-page":"S441","DOI":"10.1093\/cid\/ciac593","article-title":"Pre- and postlicensure animal efficacy studies comparing anthrax antitoxins.","volume":"75","author":"Slay","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R51","doi-asserted-by":"publisher","first-page":"S451","DOI":"10.1093\/cid\/ciac521","article-title":"Anthrax meningoencephalitis and intracranial hemorrhage.","volume":"75","author":"Caffes","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R52","doi-asserted-by":"publisher","first-page":"S478","DOI":"10.1093\/cid\/ciac537","article-title":"Risk factors for severe cutaneous anthrax in a retrospective case series and use of a clinical algorithm to identify likely meningitis and evaluate treatment outcomes, Kyrgyz Republic, 2005\u20132012.","volume":"75","author":"Kutmanova","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax.","volume":"361","author":"Migone","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R54","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","article-title":"A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge.","volume":"73","author":"Mohamed","year":"2005","journal-title":"Infect Immun"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R55","doi-asserted-by":"publisher","first-page":"5684","DOI":"10.1128\/AAC.00458-13","article-title":"Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax.","volume":"57","author":"Mytle","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R56","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1128\/AAC.01102-16","article-title":"Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax.","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R57","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1128\/AAC.00460-13","article-title":"Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits.","volume":"57","author":"Malkevich","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R58","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1473-3099(20)30069-4","article-title":"Effect of raxibacumab on immunogenicity of anthrax vaccine adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.","volume":"20","author":"Skoura","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R59","doi-asserted-by":"publisher","first-page":"e01590\u201317","DOI":"10.1128\/AAC.01590-17","article-title":"Development of protective immunity in New Zealand white rabbits challenged with Bacillus anthracis spores and treated with antibiotics and obiltoxaximab, a monoclonal antibody against protective antigen.","volume":"62","author":"Henning","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R60","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1128\/AAC.04606-14","article-title":"Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.","volume":"59","author":"Migone","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R61","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1128\/AAC.00972-16","article-title":"Efficacy projection of obiltoxaximab for treatment of inhalational anthrax across a range of disease severity.","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R62","first-page":"89","article-title":"[Prophylaxis of anthrax by antibiotics]","volume":"15","author":"Kebedzhiev","year":"1970","journal-title":"Antibiotiki"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R63","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3201\/eid2002.130245","article-title":"Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA.","volume":"20","author":"Sprenkle","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R64","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1086\/512372","article-title":"A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor.","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R65","first-page":"691","article-title":"Pathology of experimental inhalation anthrax in the rhesus monkey.","volume":"73","author":"Fritz","year":"1995","journal-title":"Lab Invest"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R66","first-page":"1303","article-title":"CT and MR findings of anthrax meningoencephalitis: report of two cases and review of the literature.","volume":"22","author":"Kim","year":"2001","journal-title":"AJNR Am J Neuroradiol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R67","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.3390\/ijms22105132","article-title":"When the blood hits your brain: the neurotoxicity of extravasated blood.","volume":"22","author":"Stokum","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R68","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmj.298.6674.636","article-title":"Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.","volume":"298","author":"Pickard","year":"1989","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R69","first-page":"271","article-title":"Effects of nimodipine on the cerebrovascular and neuronal changes during pneumococcal meningitis in the rat.","volume":"44","author":"Ho\u015foglu","year":"1997","journal-title":"Acta Microbiol Immunol Hung"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R70","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1097\/00003246-200007000-00060","article-title":"Reduction of intracranial pressure by nimodipine in experimental pneumococcal meningitis.","volume":"28","author":"Paul","year":"2000","journal-title":"Crit Care Med"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R71","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/svn-2016-000042","article-title":"Brain iron overload following intracranial haemorrhage.","volume":"1","author":"Garton","year":"2016","journal-title":"Stroke Vasc Neurol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R72","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1007\/s12035-015-9318-8","article-title":"Minocycline protects against NLRP3 inflammasome-induced inflammation and P53-associated apoptosis in early brain injury after subarachnoid hemorrhage.","volume":"53","author":"Li","year":"2016","journal-title":"Mol Neurobiol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R73","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1515\/biol-2019-0067","article-title":"Minocycline attenuates experimental subarachnoid hemorrhage in rats.","volume":"14","author":"Li","year":"2019","journal-title":"Open Life Sci"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R74","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.20850","article-title":"Evaluating therapeutic targets for reperfusion-related brain hemorrhage.","volume":"59","author":"Maier","year":"2006","journal-title":"Ann Neurol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R75","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12031-012-9769-6","article-title":"Potential contribution of hypoxia-inducible factor-1\u03b1, aquaporin-4, and matrix metalloproteinase-9 to blood-brain barrier disruption and brain edema after experimental subarachnoid hemorrhage.","volume":"48","author":"Wang","year":"2012","journal-title":"J Mol Neurosci"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuroscience.2019.06.038","article-title":"Minocycline preserves the integrity and permeability of BBB by altering the activity of DKK1-Wnt signaling in ICH model.","volume":"415","author":"Wang","year":"2019","journal-title":"Neuroscience"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R77","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-211-98811-4_26","article-title":"Minocycline attenuates brain edema, brain atrophy and neurological deficits after intracerebral hemorrhage.","volume":"106","author":"Wu","year":"2010","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1179\/174313209X385680","article-title":"Minocycline reduces intracerebral hemorrhage-induced brain injury.","volume":"31","author":"Wu","year":"2009","journal-title":"Neurol Res"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R79","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12975-019-00739-2","article-title":"Quantitative iron neuroimaging can be used to assess the effects of minocycline in an intracerebral hemorrhage minipig model.","volume":"11","author":"Yang","year":"2020","journal-title":"Transl Stroke Res"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R80","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1161\/STROKEAHA.111.623926","article-title":"Minocycline-induced attenuation of iron overload and brain injury after experimental intracerebral hemorrhage.","volume":"42","author":"Zhao","year":"2011","journal-title":"Stroke"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R81","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/978-3-319-18497-5_62","article-title":"Minocycline attenuates iron-induced brain injury.","volume":"121","author":"Zhao","year":"2016","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R82","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1177\/0333102417703764","article-title":"Region-specific disruption of the blood-brain barrier following repeated inflammatory dural stimulation in a rat model of chronic trigeminal allodynia.","volume":"38","author":"Fried","year":"2018","journal-title":"Cephalalgia"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R83","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3171\/2010.6.JNS10207","article-title":"The role of hypoxia-inducible factor-1\u03b1, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury.","volume":"114","author":"Higashida","year":"2011","journal-title":"J Neurosurg"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R84","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.brainres.2007.10.052","article-title":"Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase.","volume":"1188","author":"Nagel","year":"2008","journal-title":"Brain Res"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R85","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.brainres.2006.11.041","article-title":"Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: differences in response based on strains and solvents.","volume":"1133","author":"Rosenberg","year":"2007","journal-title":"Brain Res"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R86","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.expneurol.2005.12.016","article-title":"Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus.","volume":"198","author":"Ryu","year":"2006","journal-title":"Exp Neurol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R87","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neuroscience.2015.07.051","article-title":"Minocycline ameliorates hypoxia-induced blood-brain barrier damage by inhibition of HIF-1\u03b1 through SIRT-3\/PHD-2 degradation pathway.","volume":"304","author":"Yang","year":"2015","journal-title":"Neuroscience"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R88","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.nbd.2018.02.012","article-title":"Vascular tight junction disruption and angiogenesis in spontaneously hypertensive rat with neuroinflammatory white matter injury.","volume":"114","author":"Yang","year":"2018","journal-title":"Neurobiol Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R89","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nbd.2006.11.012","article-title":"TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice.","volume":"26","author":"Zhao","year":"2007","journal-title":"Neurobiol Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R90","doi-asserted-by":"publisher","first-page":"9685","DOI":"10.1073\/pnas.0600554103","article-title":"Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations.","volume":"103","author":"Alano","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R91","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bcp.2009.07.028","article-title":"Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells.","volume":"79","author":"Garcia-Martinez","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R92","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/1073858405275175","article-title":"Minocycline as a neuroprotective agent.","volume":"11","author":"Stirling","year":"2005","journal-title":"Neuroscientist"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R93","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature03180","article-title":"Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R94","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1111\/j.1471-4159.2004.02837.x","article-title":"Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone.","volume":"91","author":"B\u00f6ttcher","year":"2004","journal-title":"J Neurochem"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R95","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1128\/AAC.00674-12","article-title":"Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.","volume":"56","author":"Grandgirard","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R96","doi-asserted-by":"publisher","first-page":"108.e9","DOI":"10.1016\/j.cmi.2018.03.039","article-title":"Adjuvant non-bacteriolytic and anti-inflammatory combination therapy in pneumococcal meningitis: an investigation in a mouse model.","volume":"25","author":"Klein","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R97","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1111\/j.1468-1331.2007.01868.x","article-title":"Anthrax meningoencephalitis successfully treated.","volume":"14","author":"Bindu","year":"2007","journal-title":"Eur J Neurol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R98","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/CCM.0b013e3182120d13","article-title":"Superior effect of hypertonic saline over mannitol to attenuate cerebral edema in a rabbit bacterial meningitis model.","volume":"39","author":"Liu","year":"2011","journal-title":"Crit Care Med"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R99","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1093\/jpids\/piy056","article-title":"Safety and tolerability of moxifloxacin in children.","volume":"7","author":"Dixit","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R100","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/cid\/ciy416","article-title":"Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis.","volume":"67","author":"Garcia-Prats","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R101","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1128\/AAC.01404-15","article-title":"Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis.","volume":"59","author":"Garcia-Prats","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R102","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1097\/INF.0000000000001910","article-title":"Moxifloxacin in pediatric patients with complicated intra-abdominal infections: results of the MOXIPEDIA randomized controlled study.","volume":"37","author":"Wirth","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R103","doi-asserted-by":"publisher","first-page":"e20162706","DOI":"10.1542\/peds.2016-2706","article-title":"The use of systemic and topical fluoroquinolones.","volume":"138","author":"Jackson","year":"2016","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R104","unstructured":"American Academy of Pediatrics. Red book 2021\u20132024: report of the Committee on Infectious Diseases. 32nd ed. Atlanta, GA: American Academy of Pediatrics; 2021."},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R105","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jpeds.2015.02.015","article-title":"No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever.","volume":"166","author":"Todd","year":"2015","journal-title":"J Pediatr"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R106","unstructured":"Cooper C. Safety of long term therapy with penicillin and penicillin derivatives. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/bioterrorism-and-drug-preparedness\/safety-long-term-therapy-penicillin-and-penicillin-derivatives"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R107","unstructured":"Merrem IV (meropenem for injection) [Package Insert]. New York, NY: Pfizer; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/050706s041lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R108","unstructured":"Primaxin (imipenem and cilastatin) [Package Insert]. Rahway, NJ: Merck Sharp & Dohme; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/050587s081lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R109","unstructured":"Anthrax Expert Forum. Atlanta, GA: CDC, June 28\u201330, 2021."},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R110","unstructured":"Cleocin HCL (clindamycin hydrochloride) [Package Insert]. New York, NY: Pfizer; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050162s102lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R111","unstructured":"UpToDate. Clindamycin (systemic): drug information. Kennesaw, GA: Wolters Kluwer. https:\/\/www.uptodate.com\/contents\/clindamycin-systemic-drug-information?search=clindamycin&source=panel_search_result&selectedTitle=1~145&usage_type=panel&showDrugLabel=true&display_rank=1"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R112","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/jac\/dkv115","article-title":"Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis.","volume":"70","author":"Thornhill","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R113","unstructured":"UpToDate. Linezolid: drug information. Kennesaw, GA: Wolters Kluwer. https:\/\/www.uptodate.com\/contents\/linezolid-drug-information?search=linezolid&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R114","unstructured":"Zyvox (linezolid) [Package Insert]. New York, NY: Pfizer; 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021130s042,021131s038,021132s041lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R115","unstructured":"Food and Drug Administration. Package insert and patient information\u2014Anthrasil (anthrax immune globulin intravenous [human]). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2023. Rhttps:\/\/www.fda.gov\/media\/91577"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R116","unstructured":"Raxibacumab [Package Insert]. Baltimore, MD: Emergent Biosolutions; 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125349s026lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R117","unstructured":"Anthim (obiltoxaximab) [Package Insert]. Parsippany, NJ: Elusys Therapeutics; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125509s015lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R118","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/j.clinthera.2016.07.170","article-title":"Pharmacokinetics and tolerability of obiltoxaximab: a report of 5 healthy volunteer studies.","volume":"38","author":"Nagy","year":"2016","journal-title":"Clin Ther"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R119","first-page":"176","article-title":"A major epidemic of anthrax in Zimbabwe. The experience at the Beatrice Road Infectious Diseases Hospital, Harare.","volume":"31","author":"Davies","year":"1985","journal-title":"Cent Afr J Med"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R120","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jama.287.7.863","article-title":"Fatal inhalational anthrax in a 94-year-old Connecticut woman.","volume":"287","author":"Barakat","year":"2002","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R121","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/jac\/dkh258","article-title":"Selection of Bacillus anthracis isolates resistant to antibiotics.","volume":"54","author":"Athamna","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R122","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0924-8579(01)00464-2","article-title":"In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones.","volume":"18","author":"Brook","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R123","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1128\/AAC.46.7.2307-2309.2002","article-title":"Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000.","volume":"46","author":"Cavallo","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R124","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4142\/jvs.2019.20.1.58","article-title":"Evaluation of in vitro antimicrobial susceptibility of Bacillus anthracis strains isolated during anthrax outbreaks in Italy from 1984 to 2017.","volume":"20","author":"Manzulli","year":"2019","journal-title":"J Vet Sci"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R125","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1128\/JCM.40.6.1902-1907.2002","article-title":"Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods.","volume":"40","author":"Mohammed","year":"2002","journal-title":"J Clin Microbiol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R126","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cimid.2012.02.005","article-title":"Antimicrobial susceptibility and molecular subtyping of 55 Turkish Bacillus anthracis strains using 25-loci multiple-locus VNTR analysis.","volume":"35","author":"Ortatatli","year":"2012","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R127","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2146\/ajhp080152","article-title":"Stability of extemporaneously prepared moxifloxacin oral suspensions.","volume":"66","author":"Hutchinson","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R128","unstructured":"CDC. In an anthrax emergency: how to prepare doxycycline hyclate for children and adults who cannot swallow pills. US Department of Health and Human Services, CDC; 2020. https:\/\/www.cdc.gov\/anthrax\/public-health\/doxy-crushing-instruction-pamphlet.html"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R129","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax.","volume":"167","author":"Friedlander","year":"1993","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R130","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey.","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg (Lond)"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R131","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.1016\/j.vaccine.2020.10.053","article-title":"Evaluation of BioThrax\u00ae and AV7909 anthrax vaccines in adults 66 years of age or older.","volume":"38","author":"Wolfe","year":"2020","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R132","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1128\/AAC.05724-11","article-title":"Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.","volume":"56","author":"Louie","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R133","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.1128\/AAC.01376-15","article-title":"Efficacy of single and combined antibiotic treatments of anthrax in rabbits.","volume":"59","author":"Weiss","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R134","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3201\/eid0103.950301","article-title":"Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment.","volume":"1","author":"Stevens","year":"1995","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R135","doi-asserted-by":"publisher","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: mechanisms of action and resistance.","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R136","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1097\/AOG.0b013e318270ec08","article-title":"Anthrax cases in pregnant and postpartum women: a systematic review.","volume":"120","author":"Meaney-Delman","year":"2012","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R137","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.reprotox.2019.02.002","article-title":"Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: a systematic review and meta-analysis.","volume":"85","author":"Acar","year":"2019","journal-title":"Reprod Toxicol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R138","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/1471-0528.15119","article-title":"The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis.","volume":"125","author":"Yefet","year":"2018","journal-title":"BJOG"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R139","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11095-018-2383-8","article-title":"Pregnancy outcomes following exposure to quinolone antibiotics\u2014a systematic review and meta-analysis.","volume":"35","author":"Ziv","year":"2018","journal-title":"Pharm Res"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R140","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/01.AOG.0000216197.26783.b5","article-title":"Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks.","volume":"107","author":"Nahum","year":"2006","journal-title":"Obstet Gynecol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R141","first-page":"1001","article-title":"Multiple dose pharmacokinetics of ciprofloxacin in preterm babies.","volume":"41","author":"Aggarwal","year":"2004","journal-title":"Indian Pediatr"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R142","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/17425255.2019.1655540","article-title":"Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle.","volume":"15","author":"Allegaert","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R143","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00006454-199703000-00002","article-title":"Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics.","volume":"16","author":"Bradley","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R144","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/INF.0b013e318170f8d2","article-title":"Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.","volume":"27","author":"Bradley","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R145","doi-asserted-by":"crossref","unstructured":"Bradley JS, Nelson JD, eds. Nelson\u2019s pediatric antimicrobial therapy. 29th ed. Itasca, IL: American Academy of Pediatrics; 2023.","DOI":"10.1542\/9781610026512"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R146","unstructured":"Amoxil\u00ae (amoxicillin capsules, tablets, chewable tablets and powder for oral suspension) [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050760s11,050761s11,050754s12,050542s25lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R147","unstructured":"Augmentin [Package Insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R148","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","article-title":"Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline.","volume":"47","author":"Flarakos","year":"2017","journal-title":"Xenobiotica"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R149","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/INF.0000000000001538","article-title":"Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age.","volume":"36","author":"Gonzalez","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R150","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1128\/AAC.03086-15","article-title":"Clindamycin pharmacokinetics and safety in preterm and term infants.","volume":"60","author":"Gonzalez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R151","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jinf.2008.08.002","article-title":"Mycoplasma hominis meningitis in a neonate: case report and review.","volume":"57","author":"Hata","year":"2008","journal-title":"J Infect"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R152","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1097\/00006454-200012000-00012","article-title":"Single dose pharmacokinetics of linezolid in infants and children.","volume":"19","author":"Kearns","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R153","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijantimicag.2010.03.030","article-title":"Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review.","volume":"36","author":"Kocher","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R154","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1093\/jpids\/piu110","article-title":"Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children.","volume":"4","author":"Le","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R155","doi-asserted-by":"publisher","first-page":"304","DOI":"10.5863\/1551-6776-22.4.304","article-title":"Levofloxacin use in the neonate: a case series.","volume":"22","author":"Newby","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R156","doi-asserted-by":"publisher","first-page":"e02238\u201317","DOI":"10.1128\/AAC.02238-17","article-title":"Pharmacokinetics of penicillin G in preterm and term neonates.","volume":"62","author":"Padari","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R157","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clp.2014.10.009","article-title":"New antibiotic dosing in infants.","volume":"42","author":"Pineda","year":"2015","journal-title":"Clin Perinatol"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R158","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/01.ftd.0000245382.79939.a4","article-title":"Pharmacokinetics of intravenous rifampicin (rifampin) in neonates.","volume":"28","author":"Pullen","year":"2006","journal-title":"Ther Drug Monit"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R159","first-page":"121","article-title":"Clinical pharmacology of antimicrobials in premature infants. 3. Alpha-6-deoxyoxytetracycline (doxycycline).","volume":"6","author":"Simon","year":"1966","journal-title":"Antimicrob Agents Chemother (Bethesda)"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R160","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/INF.0b013e31822e8b0b","article-title":"Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections.","volume":"30","author":"Smith","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R161","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/cid\/ciw483","article-title":"Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks.","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R162","doi-asserted-by":"publisher","first-page":"S518","DOI":"10.1093\/clinids\/8.Supplement_5.S518","article-title":"Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn.","volume":"8","author":"Sutton","year":"1986","journal-title":"Rev Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R163","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1128\/AAC.37.11.2401","article-title":"Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.","volume":"37","author":"Tan","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R164","doi-asserted-by":"publisher","first-page":"e02336\u201318","DOI":"10.1128\/AAC.02336-18","article-title":"Population pharmacokinetics and dosing optimization of amoxicillin in neonates and young infants.","volume":"63","author":"Tang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"key-10.15585\/mmwr.rr7206a1-202311140847-R165","doi-asserted-by":"publisher","first-page":"CD004975","DOI":"10.1002\/14651858.CD004975.pub3","article-title":"Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media.","author":"Thanaviratananich","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R166","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1128\/AAC.02374-13","article-title":"Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design.","volume":"58","author":"Tremoulet","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R167","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/INF.0b013e31823980c3","article-title":"Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis.","volume":"31","author":"Watt","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R168","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S1473-3099(16)30162-1","article-title":"Neonate with Mycoplasma hominis meningoencephalitis given moxifloxacin.","volume":"16","author":"Wildenbeest","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R169","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/INF.0b013e31829b5880","article-title":"Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children.","volume":"32","author":"Yoshizawa","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R170","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent.","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R171","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1128\/AAC.03568-14","article-title":"Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R172","unstructured":"Occupational Safety and Health Administration. Anthrax: control and prevention. Washington, DC: US Department of Labor, Occupational Safety and Health Administration. https:\/\/www.osha.gov\/anthrax\/control-prevention#specific_work"},{"key":"key-10.15585\/mmwr.rr7206a1-202311140847-R173","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMra012892","article-title":"Recognition and management of anthrax\u2014an update.","volume":"345","author":"Swartz","year":"2001","journal-title":"N Engl J Med"}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:50:07Z","timestamp":1699969807000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/72\/rr\/rr7206a1.htm?s_cid=rr7206a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":173,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11,17]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr7206a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,17]]},"published":{"date-parts":[[2023,11,17]]}}}